ADHD studies

A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning compared with Fast Transitioning from a Stimulant Medication to Atomoxetine in Pediatric and A...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

United Kingdom, Portugal, Spain

Sponsor

Eli Lilly and Company Limited

AD/HD diagnosis through EEG, a pilot study

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Iceland

Sponsor

Mentis Cura ehf.

Randomisierte, doppelblinde Studie zum Vergleich neuropsychologischer Effekte von Atomoxetin gegen Placebo im Tagesverlauf bei Kindern mit Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung unter Anwen...

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

Germany

Sponsor

Lilly Deutschland GmbH, Teichweg 3, 35396 Gießen

A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

Netherlands

Sponsor

UMCG

A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperac...

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

France, United Kingdom, Belgium, + 5 others

Sponsor

Eli Lilly and Company

Bumetanide for the Autism Spectrum Clinical Effectiveness Trial

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

Netherlands

Sponsor

UMC Utrecht

Do effects of methylphenidate decline after long-term use? A double-blind, placebo-controlled cross-over study of effects of methylphenidate on cognitive functioning and real world behavior in trea...

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

Netherlands

Sponsor

Accare

post-trial access cohort BUmetanide for Developmental DIsorders

Current recruitment status is unconfirmed.

This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.

Countries

Netherlands

Sponsor

Amsterdam UMC, location VUmc

A Phase 3, Randomised, Double-blind, Multicentre, Parallel-group, Placebo- and Active-reference, Dose-optimisation Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children...

This study isn't currently recruiting.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

Countries

France, United Kingdom, Austria, + 7 others

Sponsor

Shire Pharmaceutical Development Ltd

A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...

This study isn't currently recruiting.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

Countries

Belgium, Germany, Netherlands, + 2 others

Sponsor

Takeda Development Center Americas, Inc.

Computer Enabled Neuroplasticity Treatment (CENT)

This study isn't currently recruiting.

Countries

Finland

Sponsor

University of Helsinki

MELatonin for children with idiopathic chronic sleep onset insomnia, with or without attention deficit hyperkinesia disorder - a DOSe finding study: a parallel group study

This study isn't currently recruiting.

Countries

Netherlands

Sponsor

Hospital Pharmacy of the Valley of Gelderland (Ziekenhuisapotheek Gelderse Vallei) (The Netherlands)